No products in the cart.
Pre-made Caplacizumab benchmark antibody ( Nanobody, anti-VWF therapeutic antibody, Anti-F8VWF/VWD Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-093
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.
| Products Name (INN Index) | Pre-Made Caplacizumab biosimilar, Nanobody, Anti-VWF Antibody: Anti-F8VWF/VWD therapeutic antibody |
|---|---|
| INN Name | Caplacizumab |
| Target | VWF |
| Format | Nanobody |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Ablynx |
| Conditions Approved | Thrombotic thrombocytopenic purpura |
| Conditions Active | NA |
| Conditions Discontinued | Thrombosis |
| Development Tech | Nanobody Technology |
| Previous Name | NA |
| Gm Offical Target Name | VWF |
| Package |
Previous slide
Next slide
